According to the American Cancer Society, about 22,530 women will receive a new diagnosis of ovarian cancer this year. In this video series , Drs. Mark Einstein, Jenna Marcus, and Stuart Lichtman discuss new therapeutics, surgical innovations, and treatment options for primary and advanced/recurrent ovarian cancer.
This video roundtable was produced by the Custom Programs division. The faculty received modest honoraria from Custom Programs for participating in this roundtable.
The faculty was solely responsible for the content presented.
Dr. Einstein discloses that he has participated in educational speaking activties for Altum Pharma, Cynvec, Papivax, PDS Biotechnologies, and Photocure. He also was the overall or local primary investigator for clinical trials for AstraZeneca, Becton-Dickinson, Inovio, Johnson & Johnson, Pfizer, and PDS Biotechnologies.
Dr. Marcus has no conflicts to disclose.
Dr. Lichtman has no conflicts to disclose.